Merck Serono spin-out to work on PD

A new spin-out of Merck Serono SA is being created to exploit molecules targeting two receptors in the G-protein-coupled receptor family of proteins with the goal of developing a treatment for Parkinson’s disease. François Conquet is to be the CEO.